FDA, Mayo Clinic Launch Convalescent Plasma Expanded Access Program

By Beth Wang / April 3, 2020 at 4:11 PM
FDA, Mayo Clinic and the American Red Cross have launched a nationwide expanded access program to collect and provide investigational convalescent plasma therapy to COVID-19 patients in the United States, especially those who may not have access to clinical trials. The agency also will work with the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to study hyperimmune globulin, which is a biological product manufactured from convalescent plasma. FDA is working with industry and government partners to...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.